Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Stopped early · Phase 3

Conditions studied: Healthy Volunteers

In brief

Hepatitis B Virus Antibody Booster Program

Key facts

Study ID

NCT01311674

Run by

Emergent BioSolutions

People needed

141

Starts

2009-09-01

Expected to finish

2011-03-11

Last updated by the study team

2024-03-18

Who can join

Age: 20 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 20-55 years.
• Naïve or previously hepatitis B-vaccinated males or females.
• Normal and healthy as determined by medical history, physical exam, vital signs and clinical laboratory tests
• Subject must meet all required/recommended subject suitability criteria that pertain to normal source plasma donors with the following exception:
• Subjects who previously tested positive for HBsAg may be accepted into the anti- HBs program provided they now test negative and meet all other normal donor suitability criteria.
• Written informed consent.

You may not qualify if…

• Subjects who have received a hepatitis B vaccination in the previous six months.
• History of hypersensitivity to yeast or any components of the Engerix-B® vaccine
• History of hypersensitivity to any hepatitis B-containing vaccine.
• Use of any investigational product within the past 30 days or during the course of the study.
• Use of steroids or immunosuppressives during the study period.
• Received immunosuppressive therapy (including systemic steroids) within 30 days before study entry
• Subjects who have received cytotoxic therapy (in the previous 5 years prior to study entry)
• Received parenteral immune globulin products or blood products within 3 months before study entry with the following exceptions:
• RhoGAM (or equivalent anti-D immune globulin) within 6 weeks before study entry;
• Pertussis immune globulin: no exclusion
• Received parenteral immune globulin products or blood products (within 3 months before study entry)
• Past, present, or suspected IV drug use
• Positive HIV, HBV* or HCV test result (*except as described above in Inclusion Criteria)
• Autoimmune disease (such as, but not limited to demyelinating disease)
• Subjects with cancer, heart disease (including hospitalization for myocardial infarction, arrhythmia, syncope, congestive heart failure), uncontrolled hypertension, uncontrolled insulin-dependent diabetes mellitus, seizures, kidney disease
• Severely or morbidly obese, or higher obesity classification, which corresponds to BMI of 35 or higher
• Pregnancy or lactation.

Where it is running

• Cangene Plasma Resources, Mid-Florida — Altamonte Springs, Florida, United States
• Cangene Plasma Resources, Frederick — Frederick, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.